Grifols SA
1GRF
Company Profile
Business description
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
Contact
Avinguda de la Generalitat, 152
Parc de Negocis Can Sant Joan
Sant Cugat del Valles
Barcelona08174
ESPT: +34 935712200
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
23,554
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,053.20 | 142.30 | -1.74% |
| CAC 40 | 7,774.41 | 141.67 | -1.79% |
| DAX 40 | 22,041.48 | 420.04 | -1.87% |
| Dow JONES (US) | 41,180.81 | 403.09 | -0.97% |
| FTSE 100 | 8,544.83 | 114.02 | -1.32% |
| HKSE | 23,119.58 | 307.02 | -1.31% |
| NASDAQ | 16,888.71 | 434.28 | -2.51% |
| Nikkei 225 | 35,617.56 | 1,502.77 | -4.05% |
| NZX 50 Index | 12,270.00 | 17.46 | -0.14% |
| S&P 500 | 5,494.95 | 85.99 | -1.54% |
| S&P/ASX 200 | 7,843.40 | 138.60 | -1.74% |
| SSE Composite Index | 3,335.75 | 15.56 | -0.46% |